Welcome to our dedicated page for Spyre Therapeutics SEC filings (Ticker: SYRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Spyre Therapeutics, Inc. (SYRE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Spyre is a clinical-stage biotechnology company listed on the Nasdaq Global Select Market, and its filings document material events, financing activities, and key clinical development updates related to its long-acting antibody programs for inflammatory bowel disease and rheumatic diseases.
Recent Form 8-K reports describe, for example, interim Phase 1 results for SPY003, an investigational extended half-life antibody targeting the p19 subunit of IL-23, including safety and pharmacokinetic findings that the company states support potential quarterly or twice-yearly maintenance dosing. Other 8-K filings detail the initiation and structure of the SKYLINE Phase 2 platform trial in ulcerative colitis and the SKYWAY Phase 2 basket trial in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, as well as financial results and preliminary cash balances for specific quarters.
Spyre’s filings also include disclosures about public equity offerings under its shelf registration statement on Form S-3. An 8-K dated October 15, 2025, for example, outlines the terms of an underwritten public offering of common stock, gross proceeds, and the company’s stated intention to use net proceeds to advance programs in IBD and rheumatic diseases, support preclinical and clinical work, manufacturing, and Phase 3 readiness activities, and provide working capital.
On Stock Titan, users can review these filings in sequence and use AI-powered tools to summarize lengthy documents, highlight key sections, and quickly identify items related to clinical data, financing, and other material events disclosed by Spyre Therapeutics.
Spyre Therapeutics, Inc. files a shelf registration to offer up to
The prospectus supplement states an at-the-market sales agreement with TD Cowen to sell up to
This shelf allows multiple offering methods and will be used for working capital, R&D, potential in-licensing or acquisitions, and general corporate purposes; offering specific terms and proceeds treatment will be set in prospectus supplements.
Spyre Therapeutics reported fourth quarter and full year 2025 results and highlighted progress across its IBD and rheumatic disease pipeline. The company is running two Phase 2 trials: the SKYLINE platform study in ulcerative colitis and the SKYWAY basket trial in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, with six proof-of-concept readouts planned in 2026.
As of December 31, 2025, Spyre held $756.5 million in cash, cash equivalents, and marketable securities and expects this to fund operations into the second half of 2028. Fourth quarter 2025 R&D expenses were $44.6 million, down from $50.5 million a year earlier, while G&A expenses rose to $12.5 million from $10.8 million.
Other expense in the quarter was $5.4 million, mainly from changes in a contingent value right liability, leading to a quarterly net loss of $62.5 million versus $56.3 million in 2024. For full year 2025, net loss was $155.2 million, compared with $208.0 million in 2024. Spyre also strengthened its balance sheet with an October 2025 underwritten public offering that generated $316.2 million in gross proceeds before $19.8 million in discounts and offering costs.
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company developing long-acting antibody therapies for inflammatory bowel disease and rheumatic diseases. Its core monoclonal antibodies target α4β7 (SPY001), TL1A (SPY002 and SPY072), and IL‑23 (SPY003), including fixed-dose combinations SPY120, SPY130, and SPY230.
The company is running the SKYLINE Phase 2 platform trial in ulcerative colitis and the SKYWAY Phase 2 basket trial of SPY072 in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, with multiple data readouts expected in 2026 and 2027. Spyre reported approximately
Tang Capital Management, Kevin Tang and related funds report a 2.4% passive stake in Spyre Therapeutics, Inc. common stock. They disclose beneficial ownership of 1,892,200 shares, with no sole voting or dispositive power and shared authority over all reported shares.
The group notes that Spyre had 77,592,130 shares outstanding as of October 29, 2025 to calculate this percentage. They also certify the shares were not acquired, and are not held, to change or influence control of Spyre Therapeutics.
Spyre Therapeutics, Inc.'s Chief Executive Officer and director Turtle Cameron reported two open-market sales of common stock. On February 2, 2026, Cameron sold 957 shares at a weighted average price of
The filing states these transactions were executed under a Rule 10b5-1 trading plan adopted on
Spyre Therapeutics, Inc. director Michael Thomas Henderson reported receiving 63,227 shares of common stock on January 21, 2026. The shares were received for no cash consideration through a pro-rata distribution from a limited liability company in which he is a member, rather than through an open-market purchase. Following this distribution, he beneficially owns 168,606 shares of Spyre Therapeutics common stock in direct form.
Spyre Therapeutics, Inc. reported an insider equity award to its Chief Financial Officer, Scott L. Burrows, in a Form 4 filing. On January 9, 2026, he was granted a stock option to purchase 140,000 shares of Spyre Therapeutics common stock at an exercise price of $30.61 per share. The option is a derivative security and is held directly.
The filing states that this option will vest in equal monthly installments over four years, and each vesting installment is conditioned on his continued employment with the company at the relevant vesting date. Following this grant, Burrows beneficially owns 140,000 stock options, with the option scheduled to expire on January 9, 2036.
Spyre Therapeutics, Inc. reported that its Chief Executive Officer and director, Turtle Cameron, received a grant of stock options on 01/09/2026. The award covers 528,000 stock options, each representing the right to purchase one share of Spyre Therapeutics common stock at an exercise price of $30.61 per share, with an expiration date of 01/09/2036.
According to the filing, these options will vest in equal monthly installments over four years, and each vesting date is conditioned on Cameron’s continued employment with the company. Following this grant, Cameron beneficially owns 528,000 derivative securities directly in the form of these stock options.
Spyre Therapeutics, Inc. reported that its Chief Medical Officer, Sloan Sheldon, received a stock option grant on January 9, 2026. The award covers options to purchase 140,000 shares of Spyre’s common stock at an exercise price of $30.61 per share, expiring on January 9, 2036. Following this grant, Sloan Sheldon beneficially owns 140,000 stock options directly. The option will vest in equal monthly installments over four years, conditioned on continued employment with the company at each vesting date.
Spyre Therapeutics, Inc. reported a new stock option grant to an executive officer. Chief Legal Officer and Corporate Secretary Heidy King-Jones received a stock option covering 140,000 shares of Spyre Therapeutics common stock on 01/09/2026.
The option has an exercise price of $30.61 per share and was reported as acquired with no cash paid for the option itself. The grant vests in equal monthly installments over four years, conditioned on her continued employment with the company at each vesting date. Following this grant, she beneficially owns 140,000 derivative securities directly in the form of this option.